Surgery Recovery Has Three Phases.
Every surgical wound heals through the same three phases: inflammation (days 1-5), proliferation (days 5-21), and remodeling (day 21 to 12+ months). Standard post-surgical care manages pain and prevents infection. It does nothing to accelerate the biological healing process.
Peptides target each healing phase with specific mechanisms. BPC-157 promotes angiogenesis and fibroblast proliferation during the critical early phases. TB-500 supports cell migration to the wound site. GHK-Cu optimizes collagen organization during remodeling to produce stronger, less scarred tissue.
The opportunity is in timing: the right peptide at the right phase produces better outcomes than a generic protocol applied uniformly.
Pre-Op: Preparing the Healing Environment.
Starting peptides 1-2 weeks before surgery primes tissue repair pathways before the surgical insult. This is not standard practice—surgeons do not recommend it because they are not familiar with the approach. But the biological logic is sound: upregulating repair mechanisms before the injury means they are ready to engage immediately.
Pre-op protocol: BPC-157 250 mcg subcutaneous twice daily for 7-14 days before surgery. This establishes systemic anti-inflammatory and pro-healing tissue concentration.
Important: Disclose all supplement and peptide use to your surgeon and anesthesiologist. While no direct interaction between BPC-157 and common anesthetic agents has been documented, your surgical team needs complete information. Some surgeons may ask you to stop all non-prescribed compounds 7-10 days before surgery—follow their guidance.
Phase 1: Inflammation (Days 1-5 Post-Op).
The inflammatory phase is necessary. It clears damaged tissue, fights infection, and signals repair cells to mobilize. Do not suppress it entirely—that is the problem with high-dose NSAIDs in the immediate post-operative period.
BPC-157 modulates inflammation rather than suppressing it. It shifts the inflammatory response from destructive to reparative without eliminating the immune surveillance needed to prevent infection.
Resume BPC-157 after surgical drains are removed and your surgeon clears you for recovery activities (typically 24-72 hours post-op). Start at 500 mcg subcutaneous twice daily. Do not inject directly into or immediately adjacent to the surgical wound—inject at least 2 inches from the incision site.
TB-500 can be started simultaneously. Its cell migration promotion supports the mobilization of repair cells to the wound site. 2-2.5 mg subcutaneous twice weekly.
Phase 2: Proliferation (Days 5-21).
This is the active tissue-building phase. New blood vessels form, collagen is deposited, and the wound begins to close. BPC-157's angiogenic properties are most valuable here—the new blood vessels it promotes deliver oxygen and nutrients that accelerate tissue growth.
Continue BPC-157 500 mcg twice daily and TB-500 2 mg twice weekly through this entire phase. This is not the time to reduce dosing or take breaks.
By the end of the proliferation phase, the wound should be structurally closed and initial scar tissue is forming. Pain typically decreases significantly during this phase as inflammation resolves.
Phase 3: Remodeling (Day 21+).
The remodeling phase is where scar quality is determined. Initial disorganized collagen is gradually replaced with organized, functional tissue. This process continues for 6-12 months.
GHK-Cu becomes the primary peptide in this phase. Its ability to promote organized collagen remodeling, activate decorin expression, and reduce excessive scar formation makes it the remodeling specialist.
Protocol shift at week 3: Reduce BPC-157 to 250 mcg once daily (maintenance). Taper TB-500 to 2 mg once weekly. Add GHK-Cu 1-2 mg subcutaneous daily + topical GHK-Cu on the closed incision site.
Continue GHK-Cu for 3-6 months. The remodeling phase is slow, and consistent peptide support throughout produces the best long-term tissue quality.
Surgery-Specific Adjustments.
Orthopedic (ACL, rotator cuff, joint replacement): Full BPC-157 + TB-500 protocol through rehabilitation. GHK-Cu for tendon graft and implant-tissue integration. See the ACL/tendon article for detailed protocols.
Abdominal (hernia, appendectomy, gallbladder): Oral BPC-157 for peritoneal healing and adhesion prevention. Subcutaneous BPC-157 near the incision for wound healing. Adhesion prevention is a primary concern—GHK-Cu's anti-fibrotic properties are directly relevant.
Dental (extraction, implant, jaw surgery): Oral BPC-157 for mucosal healing. Lower dose protocols (250 mcg once daily) are typically sufficient for oral surgical wounds.
Cosmetic (rhinoplasty, body contouring): GHK-Cu emphasis for scar quality from day 21 onward. Topical GHK-Cu on incision sites after full closure. BPC-157 standard protocol for the inflammatory and proliferative phases.
Always follow your surgeon's post-operative instructions first. Peptides supplement—they do not replace—standard surgical aftercare.
◆ Key Takeaway
Surgery heals in three phases: inflammation (days 1-5), proliferation (days 5-21), and remodeling (day 21+). BPC-157 and TB-500 dominate the first two phases (angiogenesis, cell migration, modulated inflammation). GHK-Cu takes over in the remodeling phase for organized collagen and scar quality. Start pre-op if possible. Disclose everything to your surgeon.